Form 4: Director John Patience Acquires 66,667 Restricted Stock Units in Accelerate Diagnostics

Director John Patience acquired 66,667 Restricted Stock Units (RSUs) in Accelerate Diagnostics on May 20, 2024, which vest on the first anniversary of the grant date.

Summary

• On May 20, 2024, John Patience, a director of Accelerate Diagnostics, Inc., was granted 66,667 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting.
• The RSUs vest on the first-year anniversary of the grant date.
• If the reporting person leaves in good standing before the vesting date, the RSUs will vest pro-rata based on months served.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock units, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative performance or concerns.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The RSUs will vest on the first anniversary of the grant date, contingent on continued service.

Industry Context

This is a standard practice for incentivizing and retaining board members in publicly traded companies.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a common practice among publicly traded companies to align their interests with shareholders.
• Companies like Exact Sciences and BioMerieux also use equity-based compensation for their board members.
• The vesting schedules and amounts of RSUs can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• The grant of RSUs aligns the director's interests with those of the shareholders, potentially leading to better decision-making.
• Employees may view this as a positive sign of commitment from the board.

Key Dates